🎨Science Visuals | 🎯Targeted therapies are transforming treatment for #ColorectalCancer (#CRC)
🔸Key approaches include #EGFR inhibitors like #Cetuximab & #Panitumumab and #VEGF inhibition with #Bevacizumab.
🚫#Tumor growth and #angiogenesis.
#Cancer #CancerResearch #Oncology

A modular albumin-based #BispecificTcellEngagers platform uses SpyCatcher/SpyTag for rapid tumor targeting, extended half-life, dose-dependent cytotoxicity, and stronger suppression than #Cetuximab in #BreastCancerModels.

#OpenAccess in #STTT: doi.org/10.1038/s413...

#Garsorasib, alone or with #Cetuximab, shows strong efficacy, manageable safety, and a favorable response in heavily pretreated #KRASG12C-mutated metastatic #ColorectalCancer, supporting improved precision therapy outcomes.

#OpenAccess in #STTT: doi.org/10.1038/s413...

Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer - OncoDaily Triplet of encorafenib, cetuximab, and nivolumab shows 50% response and 22-month OS in MSS BRAFV600E mCRC.

Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Encorafenib #Cetuximab #Nivolumab #ColorectalCancer #CRC #GIOnc

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation - Signal Transduction ... Signal Transduction and Targeted Therapy - Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors...

Phase II trial shows #KRASG12CInhibitor #Garsorasib, alone or with #cetuximab, delivers promising efficacy and manageable safety in heavily pretreated KRAS G12C–mutated #ColorectalCancer patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Adagrasib (Krazati) Updates 2025: Uses in Cancer, Side Effects, Dosages, Expectations, and More - OncoDaily Explore how adagrasib (Krazati) treats KRAS G12C-mutant cancers, including approvals, dosage, side effects, trial data, treatment expectations.

Adagrasib (Krazati) Updates 2025: Uses in Cancer, Side Effects, Dosages, Expectations, and More

oncodaily.com/drugs/adagra...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Adagrasib #Krazati #Cetuximab #ColonCancer #LungCancer #NSCLC

Encorafenib, cetuximab combination plus chemo boosts survival in colorectal cancer Encorafenib and cetuximab combined with chemotherapy improves progression-free and overall survival in BRAF V600E-mutated metastatic colorectal cancer.

From #ASCO25 - #Encorafenib and #cetuximab combined with chemotherapy improves progression-free and overall survival in BRAF V600E-mutated metastatic #ColorectalCancer.

Full story 👉 buff.ly/vqsPRlw

#OncSky #MedNews

FIRE-4 Study Results: Cetuximab Re-challenge in Metastatic RAS Wild-Type Colorectal Cancer - OncoDaily FIRE-4 Study Results: Cetuximab Re-challenge in Metastatic RAS Wild-Type Colorectal Cancer / ASCO, ASCO 2025 updates, ASCO 25, cancer, cetuximab, OncoDaily,

FIRE-4 Study Results: Cetuximab Re-challenge in Metastatic RAS Wild-Type Colorectal Cancer
@ascocancer.bsky.social

oncodaily.com/oncolibrary/...

#ASCO #ASCO2025Updates #ASCO25 #Cancer #Cetuximab #OncoDaily #Oncology

🔊New review in @tcrtcancer.bsky.social explores combining Cetuximab with immune checkpoint inhibitors to treat MSS/pMMR colorectal cancer.

Read the full article here: bit.ly/3GKmVgP

@journals.sagepub.com
#ColorectalCancer #Immunotherapy #Cetuximab #OncologyResearch #Oncology

The phase III NRG/RTOG 0920 trial explored adding cetuximab to postoperative radiotherapy (RT) in 577 patients with resected intermediate-risk SCCHN.

📊 Key Findings @ascocancer.bsky.social #JCO

#Onco404 #Cancer #Kanser #Oncology #HeadAndNeckCancer #RadiationTherapy #Cetuximab #ClinicalTrials #HPV

Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer - OncoDaily Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer / Arndt Vogel, BRAF mutant CRC, BRAF mutation, BREAKWATER trial, cancer, Cancer

Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer
@arndtvogel.bsky.social

oncodaily.com/blog/encoraf...

#BRAFmutant #CRC #BREAKWATERtrial #Cancer #Cetuximab #Chemotherapy #ClinicalTrials #CRC #ESMO #OncoDaily #Health #Oncology #PrecisionOncology #Medicine #TargetedTherapy

Addition of Cetuximab to Postoperative Radiotherapy in Intermediate-Risk Head and Neck Cancer In a phase III trial (NRG/RTOG 0920) reported in the Journal of Clinical Oncology, Machtay et al reviewed the addition of cetuximab to postoperative radiotherapy and its impact on survival in patients...

New findings from a phase III trial (NRG/RTOG 0920) explore the impact of adding cetuximab to postoperative radiotherapy for intermediate-risk head and neck cancer. #Cetuximab #HeadAndNeckCancer
ascopost.com/news/january...

Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - OncoDaily Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer / Braftovi, cancer, cetuximab, colorectal

FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - Maria (Masha) Babak
@thebabaklab.bsky.social
@fda.gov

oncodaily.com/blog/222646

#Braftovi #Cancer #Cetuximab #ColorectalCancer #FDA #Encorafenib #mCRC #mFOLFOX6 #OncoDaily #Oncology #Medicine #Health

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer - OncoDaily FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer / BREAKWATER trial, cancer, cetuximab,

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer
@fda.gov

oncodaily.com/insight/210177

#BREAKWATERtrial #Cancer #Cetuximab #ColorectalCancer #Encorafenib #FDA #mFOLFOX6 #OncoDaily #Oncology #Medicine #Health

Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclon...

The standard treatment for head and neck #cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: #cetuximab & #durvalumab. @ucsdmedschool.bsky.social @ucsdhealth.bsky.social

today.ucsd.edu/story/cetuxi...